Day: September 8, 2021

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) — Pure Gold Mining Inc. (TSXV:PGM LSE:PUR) (“Pure Gold Mining Inc.” or the “Company”) has today entered into an agreement with National Bank Financial Inc., as lead underwriter, on behalf of a syndicate of underwriters (collectively, the “Underwriters”) under which the Underwriters have agreed to purchase, on a bought deal basis, 19,048,000 units of the Company (“Units”) at a price of C$1.05 per Unit for gross proceeds of C$20,000,400 (the “Offering”). Each Unit is comprised of one common share (each a “Common Share”) and one-half Common Share purchase warrant (each such full warrant, a “Warrant”)....

Accelerating Heterogeneous Design and IntegrationHeterogeneous integration brings new kinds of design and manufacturing flexibility to semiconductor and systems companies by allowing chips of various technologies, functions and sizes to be integrated in one package. Applied Materials is combining its leadership in process technology and large-area substrates along with ecosystem collaborations to accelerate the industry’s heterogeneous design and integration roadmaps.New advanced software modeling and simulation for die-to-wafer hybrid bonding at Applied’s Advanced Packaging Development Center speeds customer time to market Enters into joint development agreement with EV Group for co-optimized wafer-to-wafer hybrid bonding solutions Enables larger, higher quality substrates for advanced packaging through the recent acquisition...

Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2 Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access, while contributing to sustainability of healthcare systemsBasel, September 8, 2021 — Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis in cancer, and is used in combination with other treatments1,2. Bio-Thera Solutions, Ltd. will maintain responsibility for development and manufacturing, Sandoz will...

Marks the 37th Game Developed In-House for DraftKings Casino BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) announced the addition of its new and exclusive game DraftKings Rocket to the DraftKings Casino product suite, which is currently available in New Jersey with Michigan and West Virginia to follow pending regulatory approval. Built entirely in-house, DraftKings Rocket is the latest addition to the more than 30 games that have been developed by internal team members and part of over 60 unique game builds in total. It also comes on the heels of the company’s latest iGaming expansions, which included the addition of both Spanish 21 and DKCraps earlier this year. “By developing DraftKings Rocket, our team continues to innovate our Casino offerings as we set out to create an all new, one-of-a-kind iGaming...

Company onboarded products from nearly 34 major manufacturer brands including, Ram, Ford, Honda and Toyota CRANBURY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — PARTS iD, Inc. (NYSE American: ID) (“PARTS iD” or “Company”), the owner and operator of, among other verticals, “CARiD.com,” a leading digital commerce platform for the automotive aftermarket, today provided an update on its growth within the Original Equipment (OE) parts segment. OE parts, which are the same parts used to assemble the vehicle at the factory, continue to be a high-growth area for PARTS iD, with the Company reporting 350% OE business growth in H1 2021 compared to H1 2020. In 2020, the Company invested heavily into OE product cultivation, onboarding nearly 34 major manufacturer brands including Dodge, Jeep, Hyundai and Lexus. Following this successful expansion,...

InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint measuring reductions in all three inflammatory HS lesions – including reductions of draining tunnels (previously referred to as draining fistulas) InflaRx will focus its pivotal development program on patients suffering from moderate to severe HS with active draining disease, as supported by the FDA InflaRx will incorporate FDA feedback in the study protocol for its pivotal program and submit the protocol in Q4 2021 with study activities to begin upon approval by FDAJENA, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces its plan to proceed with a pivotal development program...

MARIETTA, Ga., Sept. 08, 2021 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the shelf registration statement on Form S-3 on file with the Securities and Exchange Commission (SEC) has become effective. The shelf registration statement allows the Company to sell up to $350 million of various types of securities over the next three years. The specifics of any future offering, along with the prices and terms of any such securities and the use of proceeds of a particular offering, will be determined at the time of any such offering and will be described in a prospectus supplement filed in connection with such offering. Any offering of the securities will be made solely by means of a prospectus...

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, and Ajim Tamboli, CFA, Chief Financial Officer, are scheduled to participate in a virtual fireside chat at 2 p.m. ET on Wednesday, Sept. 15 at the Morgan Stanley 19th Annual Global Healthcare Conference. A live and archived webcast of the fireside chat will be available via the “Events & Presentations” section of the Company’s investors section of the website at https://ir.monterosatx.com/.        About Monte RosaMonte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader precision medicines. These medicines are designed to employ the body’s natural...

New Partnership Supports Development of Larger Facility to Address Food Insecurity in Wilmington Area WILMINGTON, N.C., Sept. 08, 2021 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, today announced its partnership with the Food Bank of Central & Eastern North Carolina in order to help the organization expand its food relief efforts and ensure substantial growth in its nutrition services, food access, and distribution throughout southeastern North Carolina. “The Food Bank at Wilmington is a valuable partner that provides a critical service for thousands of people in our area who suffer from food insecurity,” said Wilmington Mayor Bill Saffo. “From working families, to seniors on fixed incomes, to children and teens who...

REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it has entered into a clinical collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to investigate Bolt Biotherapeutics’ BDC-1001 in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor Opdivo® (nivolumab). BDC-1001 is a HER2-targeting Boltbody™ immune-stimulating antibody conjugate (ISAC) in development for the treatment of patients with HER2-expressing solid tumors. “We look forward to working with BMS in our continued development of BDC-1001, which has shown promising results...